The company is in the process of moving into new, larger quarters in San Carlos that it got in anticipation of FDA approval of its lead drug, which failed two late-stage clinical trials in December.
After clinical trial failures, Peninsula drug developer opts to cut 35% of jobs
The company is in the process of moving into new, larger quarters in San Carlos that it got in anticipation of FDA approval of its lead drug, which failed two late-stage clinical trials in December.
